menu
    • menu
    [{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Rifapentine","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Unitaid","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Unitaid"},{"orgOrder":0,"company":"Shanghai Pulmonary Hospital","sponsor":"Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shanghai Pulmonary Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pulmonary Hospital \/ Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Pulmonary Hospital \/ Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Beijing Chest Hospital","sponsor":"Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Beijing Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Chest Hospital \/ Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Chest Hospital \/ Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"National Defense Medical Center, Taiwan | NRPB, Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orient Pharma \/ National Defense Medical Center, Taiwan | NRPB, Taiwan","highestDevelopmentStatusID":"9","companyTruncated":"Orient Pharma \/ National Defense Medical Center, Taiwan | NRPB, Taiwan"},{"orgOrder":0,"company":"Hospital Universitari de Bellvitge","sponsor":"Cellestis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Hospital Universitari de Bellvitge","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari de Bellvitge \/ Cellestis","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Universitari de Bellvitge \/ Cellestis"},{"orgOrder":0,"company":"Bridge BioResearch","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Podiatry","graph2":"Phase II","graph3":"Bridge BioResearch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bridge BioResearch \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge BioResearch \/ Undisclosed"},{"orgOrder":0,"company":"Pharma 2100","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharma 2100","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharma 2100 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharma 2100 \/ Undisclosed"},{"orgOrder":0,"company":"University of Massachusetts, Worcester","sponsor":"National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Massachusetts, Worcester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of Massachusetts, Worcester \/ National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium","highestDevelopmentStatusID":"8","companyTruncated":"University of Massachusetts, Worcester \/ National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"TB Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ TB Alliance","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ TB Alliance"},{"orgOrder":0,"company":"University College, London","sponsor":"National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M","highestDevelopmentStatusID":"10","companyTruncated":"University College, London \/ National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000161

    Menu

    Prestwick3_000161

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University College, London

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            University College, London

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through...

                            Details : Isoniazid is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Tuberculosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : TB Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 05, 2024

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : TB Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lupin Ltd

                            India arrow
                            IPEX Indonesia
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifapentine,Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Unitaid

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment

                            Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.

                            Product Name : Rifapentine/Isoniazid-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            October 07, 2022

                            Lead Product(s) : Rifapentine,Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Unitaid

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Massachusetts, Worcester

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            University of Massachusetts, Worcester

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2021

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharma 2100

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Pharma 2100

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Healing of Ischemic Leg Ulcers in Patients Treated With iSONIAzid

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2021

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beijing Chest Hospital

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Beijing Chest Hospital

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tuberculosis, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 15, 2016

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orient Pharma

                            Taiwan arrow
                            AllPack Indonesia
                            Not Confirmed

                            Orient Pharma

                            Taiwan arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Tuberculosis, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2015

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shanghai Pulmonary Hospital

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shanghai Pulmonary Hospital

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Research on New Regimens for Retreatment Pulmonary Tuberculosis

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tuberculosis, Pulmonary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2015

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bridge BioResearch

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bridge BioResearch

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 27, 2011

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hospital Universitari de Bellvitge

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Hospital Universitari de Bellvitge

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Cellestis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

                            Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Latent Tuberculosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 19, 2010

                            Lead Product(s) : Isoniazid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Cellestis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth